Association of Naïve B Cells with Humoral Response to SARS-CoV-2 Vaccination

Eduard Schulz[1*], Isabel Hodl[2*], Patrick Forstner[3], Stefan Hatzl[1], Nazanin Sareban[4], Martina Moritz[4], Johannes Fessler[5], Barbara Dreo[2], Barbara Uhl[1], Claudia Url[4], Andrea Grisold[3], Michael Khalil[6], Barbara Kleinhappl[3], Christian Enzinger[6], Martin H. Stradner[2], Hildegard Greinix[1], Peter Schlenke[4] and Ivo Steinmetz[3]

*ES and IH contributed equally to the manuscript.

[1]Division of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
[2]Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
[3]Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria
[4]Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria
[5]Institute of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
[6]Department of Neurology, Medical University of Graz, Graz, Austria

Corresponding author:

Martin H. Stradner
Division of Rheumatology and Immunology
Department of Internal Medicine
Medical University of Graz
Auenbruggerplatz 15, 8036 Graz, Austria
Tel: +43/316/385-81794
Fax: +43/316/385-17813
E-mail: martin.stradner@medunigraz.at

Key words: mRNA vaccine, COVID-19, B cells, immunodeficiency, cancer

Word count: 2906 words

Key messages

What is already known about this subject?

► Humoral vaccination response is impaired in patients with immunodeficiency or B-cell-depleting therapies, such as anti-CD20 antibody therapy or hematopoietic stem cell transplantation.

► Current recommendations advise an interval of six months between the most recent anti-CD20 antibody administration and vaccination.

What does this study add?

► Immunocompromised patients can achieve anti-spike protein antibody levels similar to those in healthy subjects after vaccination.

► Independent of concurrent immunosuppressive treatment or condition, the number of naïve B cells, but not the total number of B cells, is strongly associated with anti-spike protein antibody levels, similar to that in healthy subjects.

How might this impact on clinical practice or future developments?

► Assessment of the abundance of naïve B cells in immunocompromised patients could be used to schedule vaccinations for optimal antibody responses.

ABSTRACT

Objectives

Immunocompromised patients are at risk of severe coronavirus disease 2019 and are considered a high priority for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Humoral vaccination response is impaired in these patients when circulating B cells are lacking. We aimed to analyze B-cell subsets at the time of vaccination to identify potential predictors of humoral vaccination response.

Methods

Patients (n=120) receiving B-cell-depleting therapy (n=41), those suffering from inborn errors of immunity (n=25) and hematologic malignancies (n=56), and healthy controls (n=79) were vaccinated twice with BNT162b2 or mRNA-1273. B-cell subsets were analyzed prior to vaccination. Two independent anti-SARS-CoV-2 S immunoassays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed three to four weeks after the second vaccination.

Results

Seroconversion occurred in 100% of the healthy controls, in contrast to 67% (RBD) and 82% (TSP) of the patients, while only 32% (RBD) and 22% (TSP) achieved antibody levels comparable to those of healthy controls. The number of circulating naïve B cell was strongly associated with antibody levels (r=0.761, P<0.001) across all immunosuppressive treatments or conditions. In multivariable analysis, the number of naïve B cells was an independent predictor for achieving antibody levels comparable to healthy controls, and receiver operating characteristic analysis predicted that at least six naïve B cells per µL were required.

Conclusions

Assessing the abundance of naïve B cells in immunocompromised patients could be useful in predicting the optimal vaccination response.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) results in increased morbidity and mortality in immunocompromised patients.[1-3] Immunodeficiency can be primary (PID) due to underlying genetic causes such as common variable immunodeficiency or secondary (SID) resulting from hematologic malignancies (HM), immunosuppressive therapies, or hematopoietic stem cell transplantation (HSCT). In a recent study of 100 patients with COVID-19 disease, patients with PID and SID demonstrated higher morbidity and mortality than the general population, while the outcomes of individuals suffering from SID were the worst.[1] In patients with HM and COVID-19, a mortality rate of 34% [95% confidence interval (CI): 28–39] has been reported in adults.[4]

Due to the high risk of severe COVID-19 in immunocompromised patients, they are considered a high priority for COVID-19 vaccination.[5-9] However, trials of the currently approved COVID-19 vaccines have excluded individuals diagnosed with immunodeficiency or malignancy; therefore, information on the efficacy and safety of the vaccines in these patients is sparse.[10-13] Hagin et al. reported specific antibody responses in 18/26 (69%) patients with inborn errors of immunity and spike-peptide-specific T cells in 19/26 (73%) patients two weeks after administration of the second dose of BNT162b2 vaccine.[10] Braun-Moscovici et al. observed significant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG antibody levels in 227/264 patients (86%) with autoimmune rheumatic diseases (AIRD) 4–6 weeks after the second dose of BNT162b2 vaccine.[11] Other investigators confirmed these vaccination responses in AIRD patients and reported significant reductions in seropositivity rates in patients receiving B-cell-depleting therapy and glucocorticoids.[12, 13] Lack of antibody responses and significantly lower antibody levels in responders have been reported in HM patient cohorts in general[14-16] and in selected patients with multiple myeloma, chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma.[17-21] Vaccinations have a low efficacy when administered soon after HSCT and anti-CD20 therapies.[5, 22, 23]

Recently, Mrak et al. showed that a humoral response to mRNA vaccines can also be induced in patients after therapy with rituximab as long as peripheral B cells are measurable.[24] However, the

number of circulating B cells or of a certain B-cell subset associated with a humoral vaccination

response comparable to healthy individuals is unknown. A marker predictive of vaccination response

would aid to schedule vaccinations in the immunocompromised to achieve optimal vaccination

response.

We hypothesize that specific B-cell subsets present during vaccination are associated with a humoral

vaccination response. Herein, we used data from an interim analysis of the prospective, open-label,

phase IV CoVVac trial (NCT04858607) to test the hypothesis.

METHODS

Study design and participants

We report the data of an interim analysis of the CoVVac trial (NCT04858607), which is an ongoing

open-label, phase IV, prospective, monocentric study at the Medical University of Graz, Austria. After

approval by the ethics committee of the Medical University of Graz in April 2021 (EK 1128/2021),

patients with inborn errors of immunity, hematological malignancies, those receiving B-cell-depleting

therapy, and healthy controls were recruited before receiving their first dose of COVID-19 vaccine.

The detailed study protocol is provided in the Supplementary Information. In brief, blood was drawn

before the first vaccination with BNT162b2 (BioNTech/Pfizer) or mRNA-1273 (Moderna) for

peripheral blood mononuclear cell (PBMC) isolation and lymphocyte phenotyping. The second

vaccination was administered 21 (BNT162b2) or 28 days (mRNA-1273) after the first. Blood

sampling was performed 21–28 days after the second vaccination to analyze the COVID-19-specific

antibody response as the primary endpoint.

Patient and public involvement

50 It was not appropriate or possible to involve patients or the public in the design, or conduct, or

51 reporting, or dissemination plans of our research.

Lymphocyte phenotyping

Blood samples from the baseline visit were processed within 4 hours for analysis by flow cytometry. For lymphocyte phenotyping, ethylenediaminetetraacetic acid whole blood was stained for CD3, CD4, CD8, CD45, CD16, CD56, and CD19, as previously described.[25] For B-cell phenotyping, PBMCs were isolated from lithium heparin whole blood by Ficoll gradient density centrifugation. One million PBMCs were incubated with the following antibodies: CD19-VioGreen, anti-IgD-VioBlue, CD24-PerCP-Vio700, CD38-FITC, CD27-APC, CD86-PE-Vio770, CD21-APC-Vio770, and anti-IgM-PE (Miltenyi Biotec, Bergisch Gladbach, Germany). Samples were measured using a FACSLyric flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using the FACSSuite (BD Biosciences). The gating strategy is shown in Supplemental Figure 1.

Antibody assays

Serum was obtained 21–28 days after the second vaccination, aliquoted, frozen, and stored at -80°C until analysis was performed in batches. Two CE-marked serological tests were performed according to the manufacturers' protocols to determine and quantify specific antibodies against SARS-CoV-2. A Specific IgG was determined using the Roche Elecsys anti-SARS-CoV-2 S electrochemiluminescence immunoassay targeting the receptor-binding domain of the viral spike protein using a Cobas e 801 analytical unit (Roche Diagnostics GmbH, Mannheim, Germany).[20, 24] Its quantification range lies between 0.4 and 2500 U/mL, with a cut-off of 0.8 U/mL for positivity. Specific IgG was measured by Liaison SARS-CoV-2 TrimericS IgG test on Liaison XL (DiaSorin, Saluggia, Italy), which is a chemiluminescence immunoassay quantifying antibodies that target the trimeric S protein.[21] Results are provided in binding antibody units (BAU) with a quantification range of 4.81–2080 BAU/mL. Values ≥33.8 BAU/mL were considered positive.

Statistical analysis

All statistical analyses were performed using Stata 16.1 (Stata Corp., Houston, TX, USA). Continuous data were reported as medians (25th–75th percentile) and categorical data as absolute frequencies (%). Correlations and associations between antibody response and other variables were examined using Spearman's rank-based correlation coefficients, rank-sum test, and χ^2-squared tests. R^2-statistics were

obtained from multiple linear regression models with antibody response as the dependent variable. The

optimal cut-off to separate patients with and without vaccination response was assessed by employing

a maximized Youden's index within a receiver operating characteristic (ROC) analysis. Logistic

models were used for univariate and multivariate modeling of the vaccination response. The Kruskal–

Wallis test was used for continuous variables when comparing three or more treatment groups. The

Kruskal–Wallis H test was used as a post-hoc test to determine between-group differences.

RESULTS

Study population

Complete data of 199 study participants who completed their full vaccination schedule were included

in the efficacy analysis. Of these, 79 were healthy participants and 120 were immunocompromised

patients. All study participants were vaccinated with mRNA-1273, with only two healthy individuals

(1%) receiving BNT162b2. A total of 140 adverse events occurred after vaccination, with the most

common being pain at the injection site, headache, fever, and fatigue. Four severe adverse events

(hospitalization and death due to HM and bone fractures) were considered unrelated to vaccination.

Participant characteristics are detailed in Table 1. Diagnoses, immunosuppressive treatments, and

antibody responses for subgroups are listed in Supplementary Table 1.

Table 1. **Baseline characteristics of the study population and rate of vaccination response.**

Variable	Overall (n=199)	Healthy (n=79)	Immunocompromised (n=120)	P
Age (years)	54 [43-62]	51 [36-56]	58 [50-65]	**<0.001**
Female gender	110 (55)	45 (57)	65 (54)	0.698
Body mass index (kg/m²)	24.4 [22.2-27.0]	23.7 [21.6-26.4]	24.8 [22.7-27.8]	**0.039**
Immunodeficiency group				n/a
Primary immunodeficiency			25 (21)	
Autoimmune disease			39 (32)	
Haematologic disease			56 (47)	
Vaccine				0.080

mRNA-1273 (Moderna)	197 (99)	77 (97)	120 (100)	
BNT162b2 (BioNTech/Pfizer)	2 (1)	2 (3)	0 (0)	
B-cell depleting therapy				n/a
None	123 (62)		44 (37)	
Rituximab	35 (18)		35 (29)	
Ocrelizumab	6 (3)		6 (5)	
HSCT	35 (17)		35 (29)	
Days since depletion			166 [69-545]	
Antibody Response				
Roche any response	159 (80)	79 (100)	80 (67)	**<0.001**
Roche stringent response	117 (59)	79 (100)	38 (32)	**<0.001**
Roche U/mL	2020 [4-2500]	2500 [2500-2500]	67 [0-1947]	**<0.001**
DiaSorin any response	177 (89)	79 (100)	98 (82)	**<0.001**
DiaSorin stringent response	105 (53)	79 (100)	26 (22)	**<0.001**
DiaSorin BAU/mL	2080 [142-2080]	2080 [2080-2080]	233 [12-1760]	**<0.001**

Data are reported as medians [25th-75th percentile] and absolute frequencies (%). P-values are from

rank-sum tests, χ2-tests, and Fisher's exact tests, as appropriate. Significant P-values are highlighted in

bold type. Any response, any seroconversion; BAU, binding antibody unit; DiaSorin stringent

response, DiaSorin SARS-CoV-2 TrimericS IgG ≥2000 BAU/mL; HSCT, haematopoietic stem stell

transplantation; Roche stringent response, Roche anti-SARS-CoV-2 S total antibody titre ≥1000

U/mL.

Immunogenicity of mRNA vaccines

Antibody responses were assessed using two different assays. All healthy controls demonstrated

seroconversion with high antibody titers (Roche median: 2500 U/mL; DiaSorin median: 2080

BAU/mL). In immunocompromised patients, the seroconversion rates and antibody levels were

significantly lower than those in healthy controls (Table 1 and Figure 1); 67% (n = 80) and 82% (n =

98) of patients demonstrated a humoral response with antibody levels within the quantification range

of Roche and DiaSorin assays, respectively. Since the clinical significance of antibody levels close to

the limit of detection was unclear, we defined more stringent thresholds. In our patients, we defined a

"stringent response" as reaching at least the lowest antibody level of the healthy individuals from our

cohort (Roche ≥1000 U/mL; DiaSorin ≥2000 BAU/mL). According to this definition, only 32%

(Roche) and 22% (DiaSorin) of patients had a stringent antibody response. This difference was not

statistically significant between the two tests (P = 0.108). Patients who received anti-CD20 therapy,

including the majority of patients with AIRD, had the lowest rate of stringent response (≤10%).

Interestingly, patients who received HSCT demonstrated a relatively high rate of stringent response

[37% (13/35)]. There was no statistically significant difference between allogeneic and autologous

HSCT (40% vs. 30%, respectively; P = 0.541). The antibody levels of both assays showed an excellent

correlation with each other (P = 0.915, P<0.001, R^2 = 0.841; Table 2; Figure 2A). Since the Roche

assay is more widely used in research and shows a good correlation with live virus neutralization tests

in vaccinated individuals,[15, 20, 24, 26] we focused on the Roche assay for subsequent analyses to

ensure comparability with other studies.

Correlation of antibody levels with the amount of B-cell subsets

The total number of B cells and all B-cell subsets were positively correlated with the antibody levels in

all patients (Roche: P = 0.739, R^2 = 0.001, P<0.001; Table 2; Figure 2B). In this analysis, the absolute

number of naïve B cells showed the highest correlation with antibody titers (Roche: P = 0.761, R^2 =

0.153; Figure 2C). Furthermore, this analysis also indicated that the time between the last B-cell-

depleting therapy and vaccination was also a significant factor correlating with antibody levels.

Extending this correlation analysis to the entire study population (Supplementary Table 2;

Supplementary Figure 2), the influence of naïve B cells remained highly significant (Roche: P = 0.636,

P<0.001, R^2 = 0.123). However, because the age of healthy subjects was significantly lower than that

of patients, age appeared to be a significant factor negatively correlated with anti-SARS-CoV-2

antibodies after vaccination in the entire study population (Roche: p = –0.209, R^2 = 0.057).

Table 2. **Correlations of SARS-CoV-2 antibody assays with different variables in the**

immunocompromised study population.

Variable	Roche anti-SARS-CoV-2			DiaSorin anti-SARS-CoV-2		
	ρ	P	R²	ρ	P	R²
Roche anti-SARS-CoV-2 S				0.915	**<0.001**	0.841
DiaSorin SARS-CoV-2	0.915	**<0.001**	0.841			

TrimericS IgG						
Age	0.091	0.321	0.001	0.086	0.349	0.005
Body mass index	0.169	0.076	0.004	0.160	0.093	0.005
Days since last B-cell depletion	0.595	**<0.001**	0.041	0.479	**<0.001**	0.063
Interval in days from last B-cell depleting therapy to vaccination up to 365 days	0.481	**0.001**	0.096	0.422	**0.002**	0.095
IgA	0.042	0.651	0.015	0.178	0.052	0.025
IgG	0.065	0.481	0.031	0.124	0.179	0.023
IgM	0.386	**<0.001**	0.002	0.424	**<0.001**	0.002
Lymphocytes abs.	0.222	0.018	0.002	0.177	0.059	0.001
T cells abs.	0.112	0.236	0.034	0.099	0.293	0.029
Cytotoxic T cells abs.	0.170	0.071	0.005	0.157	0.095	0.008
T helper cells abs.	0.025	0.789	0.062	0.037	0.693	0.045
NK cells abs.	-0.014	0.880	0.014	0.008	0.929	0.003
B cells abs.	0.739	**<0.001**	0.001	0.631	**<0.001**	0.001
CD45$^+$ cells abs.	0.227	0.015	0.002	0.192	0.041	0.001
Transitional B cells abs.	0.491	**<0.001**	0.033	0.393	**<0.001**	0.029
Naïve B cells abs.	0.761	**<0.001**	0.153	0.661	**<0.001**	0.132
Pre-switch memory B cells abs.	0.657	**<0.001**	0.004	0.572	**<0.001**	0.004
Switched memory B cells abs.	0.710	**<0.001**	0.003	0.065	**<0.001**	0.005
CD21$^-$ B cells abs.	0.640	**<0.001**	0.001	0.554	**<0.001**	0.001
Plasmablasts abs.	0.580	**<0.001**	0.001	0.523	**<0.001**	0.008

Correlations were computed with Spearman's rank-based rho adjusted for multiple testing (n=21) with

Šidák correction. The Šidák-adjusted α level is approximately 0.00244. Significant P-values are

highlighted in bold type. Abs., absolute count.

To support the results of our correlation analyses, we established a model of stringent vaccination

response prediction for the entire study population based on the results of the Roche assay using the

area under the ROC curve (AUC; Supplementary Table 3). This model suggests that the total number

of B cells (AUC: 0.87, 95% CI: 0.79–0.92), naïve B cells (AUC: 0.82, 95% CI: 0.73–0.88), pre-switch

memory B cells (AUC: 0.84, 95% CI: 0.76–0.89), and switched memory B cells (AUC: 0.85, 95% CI:

0.79–0.91) can best describe the response to vaccination in the entire study population, and that age

does not play a significant role.

Naïve B cells show the strongest association with stringent response

To test the association of variables with vaccination response determined by the Roche assay, we performed univariate and multivariate linear regression analyses on the entire study population using the same variables from the correlation analyses.

In univariate analysis (Table 3), the variables found to be significantly associated with any antibody response in patients included interval in days from the last B-cell-depleting therapy, naïve B-cell count, pre-switch memory B-cell count, and absolute number of plasmablasts. The same correlation was also found for stringent antibody responses, except for the correlation with pre-switch memory B cells. The absolute number of these B-cell subsets was significantly lower in patients than in healthy controls, in patients after monoclonal anti-CD20 antibody therapy compared to HSCT, and in patients without seroconversion compared to those with any antibody response (not shown) or stringent response (Supplementary Figure 3). The variables of immunodeficient patients stratified by vaccination response are shown in Supplementary Table 4. In the univariate analysis of the entire cohort (Supplementary Table 5), the same B-cell subsets remained significantly associated with vaccine response. In addition, we found a negative correlation with age, but only for the stringent antibody response [odds ratio (OR): 0.69 per 10-year increase, 95% CI: 0.54–0.87, P = 0.001].

Table 3. **Univariate linear regression analysis to test the association of variables with vaccination response determined by the Roche anti-SARS-CoV-2 S assay in the immunodeficient cohort.**

Variable	Any Response			Stringent Response		
	OR	95% CI	P	OR	95% CI	P
Age (per 10 years)	1.23	0.92-1.66	0.167	1.02	0.76-1.38	0.880
Body mass index (per 5 point)	1.20	0.77-1.87	0.420	1.11	0.71-0.73	0.633
Interval in days from last B-cell depleting therapy to vaccination up to 365 days (per 30 days)*	1.41	1.13-1.76	**0.002**	1.31	1.02-1.67	**0.035**
IgA (per 1g/L)	0.74	0.50-	0.136	1.30	0.87-	0.199

		1.10			1.93	
IgG (per 5g/L)	0.96	0.62-1.49	0.848	1.43	0.90-2.27	0.127
IgM (per 1g/L)	1.32	0.83-2.10	0.246	0.98	0.92-1.05	0.677
Lymphocytes abs. (per 1 G/L)	0.94	0.81-1.10	0.461	1.03	0.89-1.18	0.686
T cells abs. (per 10/µL)	1.00	0.99-1.01	0.693	1.00	0.99-1.01	0.101
Cytotoxic T cells abs. (per 10/µL)	1.01	0.99-1.02	0.143	1.00	0.99-1.01	0.846
T helper cells abs. (per 10/µL)	0.99	0.98-1.01	0.403	1.01	1.00-1.02	0.009
NK cells abs. (per 10/µL)	0.98	0.96-1.01	0.139	1.01	0.99-1.03	0.180
B cells abs. (per 10/µL)	0.99	0.99-1.01	0.401	0.99	0.99-1.01	0.931
CD45$^+$ cells abs. (per 10/µL)	0.99	0.99-1.01	0.045	1.00	0.99-1.01	0.653
Transitional B cells abs. (per 1/µL)	1.17	0.97-1.42	0.094	1.05	0.96-1.15	0.233
Naïve B cells abs. (per 10/µL)	1.17	1.07-1.28	**0.001**	1.09	1.04-1.14	**<0.001**
Pre-switch memory B cells abs. (per 10/µL)	1.78	1.09-2.92	**0.021**	1.03	0.95-1.11	0.480
Switched memory B cells abs. (per 10/µL)	0.99	0.99-1.01	0.406	0.99	0.99-1.00	0.957
CD21$^-$ B cells abs. (per 10/µL)	0.99	0.98-1.01	0.512	1.00	0.99-1.01	0.746
Plasmablasts abs. (per 1/µL)	7.95	2.68-23.4	**<0.001**	1.85	1.24-2.74	**0.002**

Significant P-values are highlighted in bold type. Any response, any seroconversion; OR, odds ratio;

stringent response, total antibody titre ≥1000 U/mL. Abs., absolute count.

In multivariable analysis for stringent response, only the number of naïve B cells was an independent

predictor (OR: 1.07 per 10-µL increase, 95% CI: 1.02–1.12, P = 0.009). The only independent

predictor of any seroconversion was plasmablast count (OR: 4.42 per 1-µL increase, 95% CI: 1.30–

15.01, P = 0.017). The interval since the last B-cell-depleting therapy had to be excluded because this

variable was not applicable to all patients.

The multivariable analyses for the entire study population are shown in Supplementary Tables 6 and 7.

The absolute number of naïve B cells remained an independent predictor of stringent antibody

response (OR: 1.14 per 10-µL increase, 95% CI: 1.08–1.20, P<0.001), while age was not associated

with vaccination response.

Exploratory analyses

As naïve B cells were the only B-cell subset independently associated with stringent antibody

response, we were interested to determine whether our dataset allowed us to estimate a naïve B cell

count threshold for stringent antibody response. ROC analysis and non-linear risk modeling predicted

that at least six or more naïve B cells per µL were required to generate a stringent vaccine response

(Figures 3A, B).

A second exploratory ROC analysis was undertaken to determine the minimum interval between the

last B-cell-depleting therapy, i.e., anti-CD20 antibody therapy or HSCT up to 365 days (n = 53), and

vaccination differentiating any seroconversion versus no vaccination response. The optimal cut-off in

this population was 116 days or more (Figure 3C).

DISCUSSION

We investigated the relationship between B-cell subsets and humoral vaccination response to

COVID-19 mRNA vaccination in immunocompromised patients and healthy controls. Recent

publications show diverging antibody levels depending on the underlying diseases of the investigated

population, age, and immunosuppressive treatments. Our findings confirm those from recent literature,

which demonstrated that immunocompromised individuals show significantly lower and more

heterogeneous antibody titers than healthy controls.[10, 11, 15, 17-21, 24]

In one of the largest studies published on COVID-19 vaccination in patients with HM, Maneikis et al.

reported lower median anti-S1 IgG responses after two BNT162b2 vaccine doses in 653 patients with

HM than 69 healthy healthcare workers.[16] However, the response was highly heterogeneous, with

many patients reaching an antibody response similar to that of healthy controls. Even in the group

treated with anti-CD20 therapy, 19% had anti-S1 IgG antibodies in the range of healthy controls.

While the factors responsible for such a favorable humoral vaccination response are unknown, a

similar heterogeneity in vaccination response has been reported for PID,[10] AIRD,[12] and

anti-CD20 therapy in several studies.[15, 16, 20, 27] Recently, Mrak et al. found that the presence of

circulating B cells was essential for the humoral response to BNT162b2 after rituximab therapy.[24]

While they found a moderate correlation with the relative abundance of circulating B cells, they state

that the mere presence of peripheral B cells allows seroconversion irrespective of the B cell count.[24]

Interestingly, in our univariate analysis, the absolute number of CD19[+] B cells prior to vaccination was

not associated with anti-SARS-CoV-2 response in patients, whereas naïve B cells, pre-switch memory

B cells, and plasmablasts were associated with seroconversion. However, only naïve B cells were

independent predictors of stringent vaccination responses (i.e., similar to healthy subjects) in the

multivariable analysis.

The abundance of circulating naïve B cells predicted stringent vaccination responses in patients across

a wide range of diseases and treatments, suggesting the functional importance of these cells in the

humoral immune response. Indeed, the production of specific antibodies to a novel antigen relies on

the presence of antigen-specific B cells within the naïve B cell pool.[28] Thus, a drastically contracted

pool of naïve B cells reduces the chance of harboring B cells with a B-cell receptor of high avidity to

the antigen. Only B cells with a high B-cell receptor/antigen avidity can interact with T follicular

helper cells successfully and subsequently undergo somatic hypermutation to develop an optimal

antibody response.[29] A lack of these cells results in low antibody titers of poor quality. Therefore,

the association of the humoral vaccination response with the abundance of naïve B cells is most likely

a causal relationship.

Establishment of protective humoral immunity following vaccination may be impaired until the naïve

B cells repopulate.[5] Therefore, current recommendations suggest time intervals of up to six months

between the most recent rituximab administration and vaccination.[30-32] Our data confirm that time

intervals play a role in seroconversion, with an estimated cut-off of 116 days from the last B-cell-

depleting therapy and vaccination. Nevertheless, several independent statistical models suggest that

B-cell subsets, the targets of these therapies, are the actual predictors of vaccination response. In a

larger cohort, Mrak et al. found that the time since the last rituximab treatment correlated with B-cell

frequency but was not an independent predictor of seroconversion.[24]

Our study had several limitations. These include single-center design and limited representation of

some patient cohorts that do not allow clear conclusions on seroconversion rates among less common

entities or less frequently used treatment strategies. Moreover, we cannot make any statements about

the persistence of the vaccination response at this point. Our study relies on the measurement of

antibodies as a surrogate for immunity to COVID-19. However, our results do not significantly differ

between the two internationally deployed anti-spike protein serological assays for detecting either total

IgG or IgG. Both tests showed a high correlation with surrogate neutralization tests, and Roche's assay

correlated well with live virus neutralization tests in vaccinated individuals.[24, 26] The strength of

our study is its prospective design and the introduction of the stringent vaccination response as a

potentially more relevant concept than seroconversion.

In summary, the humoral response to the SARS-CoV-2 mRNA vaccine is impaired in

immunocompromised patients. The abundance of circulating naïve B cells is strongly associated with

a normal antibody vaccine response across different conditions and therapies. Therefore, measuring

naïve B cells may predict the humoral response to COVID-19 vaccination. Further research is needed

to confirm these findings vaccinating immunocompromised individuals against COVID-19 and other

pathogens.

Acknowledgments

We thank Pia-Carina Gallaun and Julia Lodron for technical assistance. The samples/data used for this

project were processed with the help of the Biobank Graz of the Medical University of Graz, Austria.

Author contributions

IH, ES, PS, SH, HG, IS, and MHS designed the study. ES, IH, PF, NS, JF, BD, BU, AG, MM, CU,

MK, CE and BK collected clinical samples and/or data. PF and BK performed antibody assays. ES

and SH analyzed the data and performed the statistical analysis. ES, SH, IH, PS, HG, IS, and MHS

critically reviewed and discussed the results. ES, IH, PF, HS, HG, and MHS wrote the first draft. All

authors reviewed the draft and approved the final version of the manuscript.

Competing interests

259 None of the contributing authors have a conflict of interest, including specific financial interests,

260 relationships, and affiliations relevant to the topic or materials covered in the manuscript.

Funding

REFERENCES

1 Shields AM, Burns SO, Savic S, et al. COVID-19 in patients with primary and secondary
immunodeficiency: The United Kingdom experience, *J Allergy Clin Immunol* 2021;147:870,875.e1.

2 Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer
(CCC19): a cohort study, *Lancet* 2020;395:1907-18.

3 Hatzl S, Eisner F, Schilcher G, et al. Response to "COVID-19 in persons with haematological
cancers", *Leukemia* 2020;34:2265-70.

4 Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and
COVID-19: a systematic review and meta-analysis of 3377 patients, *Blood* 2020;136:2881-92.

5 Baker D, Roberts CAK, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting
therapy in autoimmune diseases, *Clin Exp Immunol* 2020;202:149-61.

6 Ribas A, Sengupta R, Locke T, et al. Priority COVID-19 Vaccination for Patients with Cancer while
Vaccine Supply Is Limited, *Cancer Discov* 2021;11:233-6.

7 van der Veldt, A A M, Oosting SF, Dingemans AC, et al. COVID-19 vaccination: the VOICE for
patients with cancer, *Nat Med* 2021;27:568-9.

8 Ameratunga R, Longhurst H, Steele R, et al. Common Variable Immunodeficiency Disorders, T-Cell
Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19, *J Allergy Clin Immunol*
Pract 2021.

9 Furer V, Rondaan C, Agmon-Levin N, et al. Point of view on the vaccination against COVID-19 in
patients with autoimmune inflammatory rheumatic diseases, *RMD Open* 2021;7:e001594. doi:
10.1136/rmdopen-2021.

10 Hagin D, Freund T, Navon M, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in
patients with inborn errors of immunity, *J Allergy Clin Immunol* 2021.

11 Braun-Moscovici Y, Kaplan M, Braun M, et al. Disease activity and humoral response in patients
with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-
CoV-2, *Ann Rheum Dis* 2021.

12 Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-
19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general
population: a multicentre study, *Ann Rheum Dis* 2021.

13 Deepak P, Kim W, Paley MA, et al. Glucocorticoids and B Cell Depleting Agents Substantially
Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2, *medRxiv* 2021.

14 Thakkar A, Gonzalez-Lugo JD, Goradia N, et al. Seroconversion rates following COVID-19
vaccination among patients with cancer, *Cancer Cell* 2021.

15 Greenberger LM, Saltzman LA, Senefeld JW, et al. Antibody response to SARS-CoV-2 vaccines in
patients with hematologic malignancies, *Cancer Cell* 2021 doi:10.1016/j.ccell.2021.07.012.

16 Maneikis K, Šablauskas K, Ringelevičiūtė U, et al. Immunogenicity of the BNT162b2 COVID-19
mRNA vaccine and early clinical outcomes in patients with haematological malignances in Lithuania:
a national prospective cohort study, *Lancet Haematol* 2021;8:e583-92.

17 Avivi I, Balaban R, Shragai T, et al. Humoral response rate and predictors of response to
BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma, *Br J Haematol* 2021.

18 Bird S, Panopoulou A, Shea RL, et al. Response to first vaccination against SARS-CoV-2 in
patients with multiple myeloma, *Lancet Haematol* 2021;8:e389-92.

19 Gavriatopoulou M, Terpos E, Kastritis E, et al. Low neutralizing antibody responses in WM, CLL
and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine, *Clin Exp Med* 2021:1-
5.

20 Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in
patients with chronic lymphocytic leukemia, *Blood* 2021;137:3165-73.

21 Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-
CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignances on
active treatment: preliminary data from a single institution, *J Hematol Oncol* 2021;14:81-021.

22 Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of
the immunocompromised host, *Clin Infect Dis* 2014;58:e44-100.

23 Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombinant hepatitis B vaccine
(rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants, *Blood*
2006;108:2470-5.

24 Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B
cells promote humoral immune responses in the presence of T-cell-mediated immunity, *Ann Rheum*
Dis 2021.

25 Stradner MH, Dejaco C, Brickmann K, et al. A combination of cellular biomarkers predicts failure
to respond to rituximab in rheumatoid arthritis: a 24-week observational study, *Arthritis Res Ther*
2016;18:190-016.

26 Perkmann T, Perkmann-Nagele N, Koller T, et al. Anti-Spike Protein Assays to Determine SARS-
CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays, *Microbiol Spectr*
2021:e0024721.

27 Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is significantly less
effective in patients with hematologic malignances, *Am J Hematol* 2021.

28 Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age, *Nat Rev Immunol*
2009;9:185-94.

29 Chan TD, Brink R. Affinity-based selection and the germinal center response, *Immunol Rev*
2012;247:11-23.

30 Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination
in adult patients with autoimmune inflammatory rheumatic diseases, *Ann Rheum Dis* 2020;79:39-52.

31 Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for
COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2,
Arthritis Rheumatol 2021;73:e30-45.

32 Arnold J, Winthrop K, Emery P. COVID-19 vaccination and antirheumatic therapy, *Rheumatology*
(Oxford) 2021.

FIGURE LEGENDS

Figure 1.   Immune response to SARS-CoV-2 mRNA vaccination. The scatter plot shows total Ig

levels for healthy controls, immunodeficient patients and patients after anti-CD20 therapy or

haematopoietic stem cell transplantation (HSCT). P is <0.001 between all groups calculated with the

Kruskal-Wallis test and post hoc analysis. Lines are medians with interquartile range. The Plot was

drawn with GraphPad Prism Version 9.2.0.332.

Figure 2.   Correlation of antibody levels determined by Roche anti-SARS-CoV-2 S assay with

B cells in patients. (A.) DiaSorin SARS-CoV-2 TrimericS IgG. (B.) Absolute number of B cells

(CD19[+] cells). (C.) Absolute number of naïve B cells. Scatter plots indicate a linear regression line

including a 95% confidence interval. In case of A. and B., regression line corresponds to transformed

data using $x=\log((x+1)$ and $y=\log((y+1))$, respectively.

Figure 3.   Exploratory analyses estimating the number of naïve B cells and the interval to the

last B-cell depleting therapy required for a vaccination response. (A.) The receiver operating

characteristic (ROC) analysis curve for naïve B cells differentiating stringent antibody response vs no

or any vaccination response in the whole study population (n=189) shows excellent discrimination.

(B.) A non-linear risk model based on the observed risk of seroconversion was created to estimate the

minimum number of naïve B cells required for a stringent vaccination response. Independently, the

best discriminatory cut-off (dashed line) was determined with the Youden's index from the ROC

curve. Both models predict that six or more naïve B cell per µL are required to generate a stringent

vaccine response. (C.) The ROC analysis curve for the interval since the last B-cell depleting therapy

up to 365 days (n=53) differentiating any seroconversion vs no vaccination response. The optimal cut-

off is an interval of 116 days or more.

Figure 2

Figure 3

Area under ROC curve = 0.8373

○ Observed Risk   — Expected Risk   ▨ 95% CI

Area under ROC curve = 0.7716